J Cancer 2016; 7(14):2052-2060. doi:10.7150/jca.16069

Research Paper

AIB1 Genomic Amplification Predicts Poor Clinical Outcomes in Female Glioma Patients

Lihong Chen1*, Changwei Wang2*, Xinyuan Zhang3, Ke Gao4, Rui Liu5, Bingyin Shi6,7, Peng Hou6,7✉

1. Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China
2. Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, The People's Republic of China
3. Department of Biochemistry, McMaster University, Hamilton, Ontario L8S 4L8, Canada
4. Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China
5. Department of Radio Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China
6. Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China
7. Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, The People's Republic of China.
* These authors contributed equally to this work.

Abstract

Amplified in breast cancer 1 (AIB1) gene, a coactivator for steroid receptor, is frequently amplified in diverse cancers and is considered as an oncogene in tumorigenesis. However, the prognostic significance of AIB1 amplification in gliomas remains totally unclear. In this study, 115 gliomas and 16 benign meningiomas as control subjects were enrolled, and the copy number of AIB1 was analyzed in these samples. In addition, we explored potential correlation of AIB1 amplification with clinicopathological characteristics and clinical outcomes of glioma patients. Our data showed that glioma samples exhibited a significantly higher AIB1 copy number than control subjects as determined by quantitative polymerase chain reaction (qPCR) approach. Moreover, univariate analysis showed that AIB1 amplification (≥3.5 copies) was strongly correlated with cancer-related death (P =0.03). Interestingly, our data revealed a significant association of AIB1 amplification with WHO grade (P =0.03), tumor recurrence (P =0.03) and survival status (P =0.03) in female patients but not in male patients. Multivariate analysis further demonstrated that AIB1 amplification was independent factor for cancer-related death in female patients. Importantly, AIB1 amplification was closely relevant to worse survival in female patients (P =0.001), but not in male patients (P =1.00). In addition, the patients with AIB1 amplification were resistant to radiotherapy. Altogether, our data demonstrate that AIB1 amplification is a common genetic event in glioma tumorigenesis, and suggest that AIB1 amplification is not only a prognostic factor for poor clinical outcomes in glioma patients, but also a predictor of radiotherapy resistance in gliomas.

Keywords: Glioma, AIB1 amplification, clinical outcomes, radiotherapy resistance

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Chen L, Wang C, Zhang X, Gao K, Liu R, Shi B, Hou P. AIB1 Genomic Amplification Predicts Poor Clinical Outcomes in Female Glioma Patients. J Cancer 2016; 7(14):2052-2060. doi:10.7150/jca.16069. Available from http://www.jcancer.org/v07p2052.htm